Een pil tegen melasma

Melasma is a common skin disorder, presenting with hyper-pigmentation on specific locations, mostly in the face, and can have a significant impact on quality of life. Treatments inhibit hyperpigmentation, but a recurrence almost always occurs. Many patients at the Netherlands Institute for Pigment Disorders (SNIP) are treated with the gold standard therapy hydroquinone 5% combined with tretinoin 0.05% and triamcinolone acetonide 0.1% in cremor lanette II (triple therapy). Yet this therapy is not always effective. Oral tranexamic acid, a procoagulant agent, has been used in low-dose since 1979 as a treatment option for facial melasma. The results in the literature are promising and our first experiences at the SNIP also seem show favorable results. Selection criteria apply to lower the risk of throm-boembolic events. Taking this into account, oral tranexamic acid can be considered as a treatment option for therapy resistant melasma.